Physician profile
Samreen W Azeem
NPI 1093823874
$1,614.18
in general payments reported to CMS, 2019-2025
16 companies · $191 in 2025
The $191 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $129 · 2020: $194 · 2021: $82.37 · 2022: $265 · 2023: $498 · 2024: $255 · 2025: $191.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $944.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $943.89 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $535.82 | 2019-2025 | Wegovy, Rybelsus, Ozempic |
| Astrazeneca Pharmaceuticals LP | $179.30 | 2019-2025 | Farxiga, Airsupra |
| Lilly USA, LLC | $158.27 | 2022-2025 | Mounjaro, Zepbound, Jardiance |
| Abbvie INC. | $139.37 | 2021-2025 | Qulipta, Ubrelvy, Vraylar |
| Pfizer INC. | $80.97 | 2022-2025 | |
| Merck Sharp & Dohme LLC | $76.64 | 2022-2023 | Verquvo, Belsomra, Steglatro |
| Vivus LLC | $73.62 | 2019-2020 | |
| Amgen INC. | $71.37 | 2019-2022 | |
| Exact Sciences Corporation | $57.25 | 2024-2025 | Cologuard Collection Kit |
| Idorsia Pharmaceuticals US INC | $56.34 | 2023 | Quviviq |
| Eisai INC. | $56.22 | 2020-2022 | |
| Amarin Pharma, INC. | $36.61 | 2020 | |
| Medtronic, INC. | $29.69 | 2023 | Intellis Adaptivestim |
| Currax Pharmaceuticals LLC | $27.43 | 2020-2022 | |
| Azurity Pharmaceuticals, INC. | $18.65 | 2025 | Alvesco |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ultragenyx Pharmaceutical INC. | $16.63 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Samreen Azeem listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.